Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Income (2019 - 2025)

Historic Net Income for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Net Income fell 1259.21% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$777.2 million, marking a year-over-year decrease of 7234.73%. This contributed to the annual value of -$543.3 million for FY2024, which is 1682.42% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Net Income stood at -$184.9 million, which was down 1259.21% from -$183.8 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Net Income ranged from a high of -$19.1 million in Q1 2024 and a low of -$267.4 million during Q4 2024
  • For the 5-year period, BridgeBio Pharma's Net Income averaged around -$153.4 million, with its median value being -$162.2 million (2023).
  • Per our database at Business Quant, BridgeBio Pharma's Net Income surged by 8659.48% in 2024 and then tumbled by 64071.27% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Net Income (Quarter) stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then crashed by 39.19% to -$267.4 million in 2024, then surged by 30.84% to -$184.9 million in 2025.
  • Its Net Income was -$184.9 million in Q3 2025, compared to -$183.8 million in Q2 2025 and -$141.1 million in Q1 2025.